Exploring immune responses in dogs and humans with bladder cancer
Advancing immunotherapy through cross species studies of immune cell responses and immune checkpoint inhibitor effects in dogs and humans with invasive urinary bladder cancer
This study is looking at how a type of cancer treatment called immune checkpoint inhibitors works for both dogs and humans with bladder cancer, hoping to find ways to make the treatment better for everyone.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Purdue University NIH-funded |
| Lab location | 1 site (West Lafayette, United States) |
| Project ID | NIH-10926920 on NIH RePORTER |
What this research studies
This research investigates how immune checkpoint inhibitors (ICIs) affect dogs and humans suffering from invasive urinary bladder cancer. By studying dogs with naturally-occurring bladder cancer, which closely resembles the human condition, the research aims to identify similarities and differences in immune cell responses and treatment outcomes. The findings could help improve the effectiveness of ICIs for human patients by using canine models to better predict responses and adverse effects. The study will involve comparing immune responses and treatment effects between dogs and humans to enhance our understanding of ICI therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with invasive urinary bladder cancer who may benefit from immune checkpoint inhibitor therapies.
Not a fit: Patients with bladder cancer who are not eligible for immune checkpoint inhibitors or have other unrelated health conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment outcomes for patients with invasive urinary bladder cancer through better-targeted immunotherapy.
How similar studies have performed: Previous research has shown promise in using animal models to improve human cancer therapies, indicating that this approach could yield valuable insights.
Where this research is happening
West Lafayette, United States
- Purdue University — West Lafayette, United States (Active)
Researchers
- Principal investigator: Knapp, Deborah W — Purdue University
- Study coordinator: Knapp, Deborah W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.